Strategic Alliance In Oncology Between Woodland Biosciences And CNBE de l’INRS
A Preclinical Oncology Strike Force is Now Available
Worcester and Laval, February 11, 2015. – A strategic partnership agreement in preclinical oncology was signed by Woodland Biosciences and Centre national de biologie expérimentale (CNBE) of Institut national de recherche scientifique (INRS). This unique alliance provides integrated contractual services from target discovery through preclinical development in the oncology field.
The spectrum of services comprises in vitro screening services using 2D and 3D cultures, target marker identification and mechanism of action, and in vivo pharmacology studies. In addition to standard efficacy studies, the alliance allows us to provide the following expanded and integrated menu of services making your experiment a more complete study that can be customized to your needs: screening toxicology (biodistribution, dose-range finding, immunotoxicology, chemotherapy-related hematological toxicities), pharmacokinetic, pharmacodynamic and biomarker identification in healthy and tumor bearing animals, syngeneic animal cancer models and xenograft studies using cell line and patient-derived (PDX) models for small chemical entities and biological products. Over 260 human cancer cell lines in 19 cancer indications will be available.
Further, innovative animal models of cancer will be co-developed over the next months for answering unmet needs in oncology. A critical research focus of the alliance is to better understand and model treatment-refractory or drug resistant cancers which is the clear unmet medical need for researchers, clinicians and their patients.
“Our partnership with CNBE will accelerate targeted applied oncology research and development, particularly in offering a one stop shop for anti-cancer drug developers,” explains Dr. Michael R. Briggs, President, Woodland Biosciences.
“Thanks to this agreement, the clients will be able to use the expertise of each organisation to strengthen their drug development pipeline. They will have also the possibility to expand their development in using the state-of-art animal facility of the CNBE having the expertise and capability to house rodents, dogs, ferrets, farm animals (swine, sheep and goats) and non-human primates,” adds Dr. Mario C. Filion, Director of CNBE-INRS.
Woodland is also pleased to announce that it has formed a Quebec corporation, Recherche Translationnelle Woodland Canada, Inc. (Woodland Translational Research Canada) which will be located at the CNBE on the INRS–Institut Armand Frappier campus. This organization is primarily focused on building a state-of-the-art primary patient viable tumor bank, called “Living Legacy” Viable Tumor Bank that is partnered with a Quebec-based non-profit organization, PreThera Research that has received Canadian funding from the Network of Centers of Excellence to establish the bank and identify solutions to personalizing cancer care. Woodland Canada will focus on capturing primary patient tumors, expanding them and preserving them in a viable form for future studies of new drug entities and biological products and models more relevant to the clinic for researchers from the academic and industry setting in Canada and around the world.
For more information, please see http://www.nce-rce.gc.ca/NetworksCentres-CentresReseaux/BLNCE-RCEE/PreThera_eng.asp
About Woodland Biosciences
Woodland BioSciences is a preclinical contract research organization (CRO) providing innovative and customized solutions and consultation to the biotechnology community. The mission of Woodland is to enhance drug development for the most severe cancers, inflammation and other major diseases. Woodland also enters shared-risk ventures through our bioincubator to help advance early molecules to value creation milestones.
About CNBE INRS
CNBE, located on the INRS campus in Laval, offers high standard preclinical research services to the scientific community and the biotechnology and pharmaceutical industries. Certified by the Canadian Council on Animal Care in Science (CCAC) and the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International), it provides housing for laboratory animals at various levels of biological confinement as well as an array of services required by R&D projects.
-30-
Source:
Michael R. Briggs
President
Woodland Bioscience
Worcester, MA, USA
www.woodlandbiosciences.com
Mario C. Filion
Director
CNBE INRS
Laval, Québec, Canada
www.cnbe.inrs.ca
Help employers find you! Check out all the jobs and post your resume.
Worcester and Laval, February 11, 2015. – A strategic partnership agreement in preclinical oncology was signed by Woodland Biosciences and Centre national de biologie expérimentale (CNBE) of Institut national de recherche scientifique (INRS). This unique alliance provides integrated contractual services from target discovery through preclinical development in the oncology field.
The spectrum of services comprises in vitro screening services using 2D and 3D cultures, target marker identification and mechanism of action, and in vivo pharmacology studies. In addition to standard efficacy studies, the alliance allows us to provide the following expanded and integrated menu of services making your experiment a more complete study that can be customized to your needs: screening toxicology (biodistribution, dose-range finding, immunotoxicology, chemotherapy-related hematological toxicities), pharmacokinetic, pharmacodynamic and biomarker identification in healthy and tumor bearing animals, syngeneic animal cancer models and xenograft studies using cell line and patient-derived (PDX) models for small chemical entities and biological products. Over 260 human cancer cell lines in 19 cancer indications will be available.
Further, innovative animal models of cancer will be co-developed over the next months for answering unmet needs in oncology. A critical research focus of the alliance is to better understand and model treatment-refractory or drug resistant cancers which is the clear unmet medical need for researchers, clinicians and their patients.
“Our partnership with CNBE will accelerate targeted applied oncology research and development, particularly in offering a one stop shop for anti-cancer drug developers,” explains Dr. Michael R. Briggs, President, Woodland Biosciences.
“Thanks to this agreement, the clients will be able to use the expertise of each organisation to strengthen their drug development pipeline. They will have also the possibility to expand their development in using the state-of-art animal facility of the CNBE having the expertise and capability to house rodents, dogs, ferrets, farm animals (swine, sheep and goats) and non-human primates,” adds Dr. Mario C. Filion, Director of CNBE-INRS.
Woodland is also pleased to announce that it has formed a Quebec corporation, Recherche Translationnelle Woodland Canada, Inc. (Woodland Translational Research Canada) which will be located at the CNBE on the INRS–Institut Armand Frappier campus. This organization is primarily focused on building a state-of-the-art primary patient viable tumor bank, called “Living Legacy” Viable Tumor Bank that is partnered with a Quebec-based non-profit organization, PreThera Research that has received Canadian funding from the Network of Centers of Excellence to establish the bank and identify solutions to personalizing cancer care. Woodland Canada will focus on capturing primary patient tumors, expanding them and preserving them in a viable form for future studies of new drug entities and biological products and models more relevant to the clinic for researchers from the academic and industry setting in Canada and around the world.
For more information, please see http://www.nce-rce.gc.ca/NetworksCentres-CentresReseaux/BLNCE-RCEE/PreThera_eng.asp
About Woodland Biosciences
Woodland BioSciences is a preclinical contract research organization (CRO) providing innovative and customized solutions and consultation to the biotechnology community. The mission of Woodland is to enhance drug development for the most severe cancers, inflammation and other major diseases. Woodland also enters shared-risk ventures through our bioincubator to help advance early molecules to value creation milestones.
About CNBE INRS
CNBE, located on the INRS campus in Laval, offers high standard preclinical research services to the scientific community and the biotechnology and pharmaceutical industries. Certified by the Canadian Council on Animal Care in Science (CCAC) and the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International), it provides housing for laboratory animals at various levels of biological confinement as well as an array of services required by R&D projects.
-30-
Source:
Michael R. Briggs
President
Woodland Bioscience
Worcester, MA, USA
www.woodlandbiosciences.com
Mario C. Filion
Director
CNBE INRS
Laval, Québec, Canada
www.cnbe.inrs.ca
Help employers find you! Check out all the jobs and post your resume.